Entering text into the input field will update the search result below

CryoPort: Profiting From CAR-T

Mar. 02, 2020 12:44 PM ETCryoport, Inc. (CYRX)10 Comments
BioSci Capital Partners profile picture
BioSci Capital Partners


  • Excluding a one-time stock compensation, the bottom-line improved by 28% for the 3Q2019 earnings report.
  • Powering by growth synergy and riding the industry tailwind of CAR-T, CryoPort is enjoying an extremely high revenue growth rate.
  • Despite strong developments, the bear market pushed CryoPort to trade at a deep bargain to its true worth.
  • I do much more than just articles at Integrated BioSci Investing: Members get access to model portfolios, regular updates, a chat room, and more. Get started today »

Don't fail to consider time as well as price in buying a true growth stock. - Philip Fisher

One of the secrets to successful bioscience investing is to buy a Philip Fisher's growth stock after it experienced a temporary depreciation. Better yet, the best time to purchase is amid a bear market. That's because you can pick up the same company at a deep bargain. At the turn of the next bull market cycle, your stock is most likely to gain multiple folds. Now, don't randomly purchase any stock that tumbled. That is to say, you need to check its fundamentals to see if there is an organic problem. If the stock is just undergoing market unpopularity, it'll rebound to a new high.

CryoPort (NASDAQ:CYRX) epitomizes the aforesaid phenomenon. The stock was on a tear, thus trading as high as $24.53 back on August 16, 2019. Thereafter, unusually strong pressure caused CryoPort to tumble to $13.84 two months later. It seems like market doubts are evaporating, as the stock is making a comeback. In this article, I'll present a fundamental update on CryoPort and share with you my forward expectations.

Figure 1: CryoPort chart (Source: StockCharts)

About The Company

As usual, I'll present a brief overview of the company for new investors. If you are familiar with the firm I recommend that you skip to the next section. Operating out of Irvine, California, CryoPort is operating a logistics business for the life science industry.

Banking on the industry tailwind of cell-based therapies, CryoPort provides the storage and delivery of biological specimens in a strict temperature-controlled environment. That way, they can ensure their livelihood, efficacy, and safety.

Figure 2: CryoPort logistics (Source: CryoPort)

Accordingly, there are three subsidiaries, including biopharma, human reproductive health, and animal medicine. Of those three franchises, the business generating the most value is

Thanks for reading! Please hit the orange "Follow" button on top for more. Don't miss out on the most profitable content (i.e. higher level intelligence) inside IBI. Here's what members said:

Dr. Tran's analyses are the best in the biotech sphere, well worth the price of subscription.

Very professional, extremely knowledgeable, and very honest … I would highly recommend this service, and his stock picks have been very profitable.

Not satisfied? See countless testimonies here.

I'm so confident in the value of my service that I'm giving you a 2-week FREE trial, money-back guarantee.


This article was written by

BioSci Capital Partners profile picture
As an astute devotee of Warren Buffet, Ben Graham, Phillip Fisher, Sir John Templeton, and Peter Lynch, Dr. Harvey devoured any resources/books on these gurus to learn their craft for over two decades. In the process, he refined their investment approaches specifically to biotech and founded Integrated BioSci Investing: The Number #1 Biotech Service for Long-Term Growth Investing and Power Catalyst Trading.  Since inception, our flagship portfolio has delivered over 31.23% annual average (i.e. 187.39% for roughly six years). As you can appreciate, we’re adept at assisting and serving institutional/retail investors/traders who are looking for alpha. Dividend investors wanting to boost your return can also benefit greatly from our investment research. We currently have over 20 docs in our service for us to tap into their clinical insight for your gains. Check out some of our binary event forecasts that lead to meteoric gain like the 359% single-day pop from Madrigal Pharmaceuticals (MDGL)’s NASH data release. During his training at the world-renown Columbia University, Harvey Tran, M.D., M.S., developed a passion/edge for analyzing the intricacies of various preclinical/clinical studies, biostatistics, and science/medicine. Importantly, it allowed the physician-scientist Harvey to realize the internal working of various therapeutic in-development that the market tends to overlook. In recent years, Dr. Harvey founded and led two healthcare roll-up companies. The endeavor helped him gain deep insight into the inner working of a corporate board. His experience as a consultant to common/professional investors and institutions gave him a huge advantage in biotech analysis. The combination of elite training and a passion for biotech provided Dr. Harvey with an aptitude for delivering highly accurate clinical data forecasting that is crucial to picking winning biotech investments for you.Follow us for the latest research. And, take our FREE 2-week trial to Integrated BioSci Investing to start your winning process now!Check out Dr. Harvey’s LinkTree for his complete experience. You can make your one good decision a year as Mr. Buffett recommended by checking out  Integrated BioSci Investing!

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

As a medical doctor/market expert, I'm not a registered investment advisor. Despite that I strive to provide the most accurate information, I neither guarantee the accuracy nor timeliness. Past performance does NOT guarantee future results. I reserve the right to make any investment decision for myself and my affiliates pertaining to any security without notification except where it is required by law. I'm also NOT responsible for the action of my affiliates. The thesis that I presented may change anytime due to the changing nature of information itself. Investing in stocks and options can result in a loss of capital. The information presented should NOT be construed as recommendations to buy or sell any form of security. My articles are best utilized as educational and informational materials to assist investors in your own due diligence process. That said, you are expected to perform your own due diligence and take responsibility for your action. You should also consult with your own financial advisor for specific guidance, as financial circumstance are individualized.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (10)

What is your current POV on CYRX? I feel now extremely overvalued. While the CAR-T space is a great place for profitable growth, CYRX is still a “pick shovel” play

They are/ were 18-24 months behind a company called HemaCare that was purchased by CRL in January. Compare for true enterprise valuation purposes

CYRX now at $900m in market cap appears very over extended.

Jim in Kiawah
guapo profile picture
what is your price target CYRX?
David Single profile picture
AVCO scares me a bunch. SNDX made a great recovery from the $4+ area and now back to $9. This hasn't happened to AVCO.
David Single profile picture
Great! Are you still behind CLVS as it's lost a ton for me
BioSci Capital Partners profile picture
@David Single Thanks for commenting on my article. I'm still bullish on CLVS. Even in light of the Corona bear market, CLVS ran up from $3.59 to over $8.21. You must have bought in at one of the rallies. Time is on your side when you hold a fundamentally strong stock. Though it can be easy to let your fear cause you to buy, I would hold on to CLVS. But the decision is ultimately yours to make. Enjoy your weekend, David.

Dr. Tran
Dr I hope your prediction will be a bit better than yours regarding clvs. You were way wrong on that one
BioSci Capital Partners profile picture
@jpcarvalhosa The stock increased from $3.50 to over $16. I took profits and many members made huge money on it. Then there's ITCI's 194% rally in a single day. If you're looking for something better, you won't offend me if you choose to leave.

Dr. Tran
Thank you for sharing your perspectives on CYRX, Dr. Tran.

If I may ask, how would you compare the stock to its competitor BLFS, which also looks like a bargain while being closer to profitability? Would you say that both stocks deserve to be owned in a basket approach or one is a better choice over the other?
BioSci Capital Partners profile picture
@BuckingTheTrend In biotech, doing a basket approach is a good strategy. Regardless of what strategy you use, investing in the top dog pays off.

Dr. Tran
Alpha dog: Arf Arf!
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About CYRX

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on CYRX

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.